C2i Genomics Raises $100 Million To Commercialize the Detection of Tiny Traces of Cancer Using AI and Whole Genome Sequencing
Led by Casdin Capital, the funding comes just ten months after the company’s Series A financing and will be used to expand C2i’s global network of clinical and drug development partnerships C2i Genomics, a cancer…